Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223858 | 0.83 | KDM4C (0.44) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL17594700 | 0.79 | KDM4C (0.45) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL3294827 | 0.77 | KDM4C (0.44) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL25624099 | 0.75 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL25624204 | 0.75 | KDM4C (0.39) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL29356162 | 0.74 | KDM4C (0.40) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL22468349 | 0.74 | KDM4C (0.40) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL12200512 | 0.74 | KDM4C (0.46) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL25624097 | 0.73 | KDM4C (0.38) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL971208 | 0.73 | KDM4C (0.45) | KDM4CL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004087-B1 | DERIVATIVES OF [1,2,4]TRIAZOLO[4,3-A]PYRIDINE AS P38-MAP KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-08-09 | — | — | EP | disclosed |
| EP-3004087-B1 | DERIVATIVES OF [1,2,4]TRIAZOLO[4,3-A]PYRIDINE AS P38-MAP KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9573949-B2 | Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-21 | — | — | US | disclosed |
| US-9573949-B2 | Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-21 | — | — | US | disclosed |
| US-9573949-B2 | Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-21 | — | — | US | disclosed |
| US-20160108040-A1 | DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-21 | — | — | US | disclosed |
| US-20160108040-A1 | DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-21 | — | — | US | disclosed |
| US-20160108040-A1 | DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-21 | — | — | US | disclosed |
| EP-3004087-A1 | DERIVATIVES OF [1, 2, 4]TRIAZOLO [4, 3 - A]PYRIDINE AS P38 - MAP KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014194956-A1 | DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108040-A1 | DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | KDM4C 4010/4885L3MBTL1 4315/4885NPC1 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.